Skip to main content

Table 4 Therapy targeting the Wnt/β-catenin signalling pathway in haematological malignancies

From: The Wnt/β-catenin signalling pathway in Haematological Neoplasms

Factor

Target

Disease

Clinical Trials

CWP232291

β-catenin

AML

NCT01398462 [116]

PRI-724

CBP/β-catenin

AML/CML

NCT01606579 [117]

Lawsone

FZD

ALL

[118]

WNT974

β-catenin

lymphoma

[119, 120]

PRMT5

Wnt/β-catenin and AKT/GSK3β

lymphoma

[121]

AV-65

β-catenin

MM

[122]

DAC/BZM

β-catenin/GSK3β

MM

[123]

BC2059

β-catenin

MM

[124]

panobinostat/Tegavivint

β-catenin

MM

[125]